Core Viewpoint - Weigao Blood Purification announced the approval to use raised funds to replace 277 million yuan of self-raised funds for investment projects and issuance expenses [1] Summary by Relevant Sections Fund Replacement - The company will replace 240 million yuan for investment projects and 36.6352 million yuan for issuance expenses, totaling 277 million yuan [1] Fundraising Details - The total amount raised is 1.09 billion yuan, with a net amount of 978 million yuan [1] - The investment projects include the Weigao Blood Purification Intelligent Production Construction Project and the Dialyzer (Ganzhou) Production Construction Project [1] Fund Management - The raised funds have been deposited into a special account, and the company will conduct an equivalent replacement [1]

（文章来源：证券时报网） 佳合科技 | 301501 | 恒鑫生活 | 78.88 | 35.12 | -6.79 | | --- | --- | --- | --- | --- | | 603014 | C威高 | 37.11 | 34.65 | -4.53 | | 688755 | C汉邦 | 46.83 | 34.54 | -4.82 | | 920068 | 天工股份 | 20.90 | 33.73 | -7.11 | | 870299 | 灿能电力 | 23.78 | 33.65 | -5.63 | | 001206 | 依依股份 | 24.35 | 33.46 | 6.15 | | 300040 | 九洲集团 | 8.10 | 33.26 | -4.48 | | 301488 | 豪恩汽电 | 76.00 | 32.75 | -2.25 | | 600610 | 中毅达 | 15.79 | 32.63 | -5.11 | | 300703 | 创源股份 | 18.58 | 32.49 | -2.31 | | 837023 | 芭薇股份 | 29.28 | 32.19 | -4.38 | | 301 ...

Group 1 - C Weigao (603014) saw a first-day increase of 56.26%, with a turnover rate of 69.71% and a transaction volume of 1.15 billion yuan [2] - The stock had a net inflow of 178 million yuan from major funds on its first trading day, with large orders contributing 130 million yuan [3] - The stock's first-day financing amount was 39.74 million yuan, accounting for 3.46% of the total trading volume, with a latest financing balance of 34.33 million yuan, representing 2.18% of the circulating market value [2][3] Group 2 - C Weigao specializes in the research, production, and sales of blood purification medical products [3] - On the first trading day, the top five trading departments on the dragon and tiger list had a total transaction of 175 million yuan, with a net selling of 10.46 million yuan [3] - The financing balance for C Weigao on its first day was 34.33 million yuan, with no short selling balance recorded [3]

Policy Developments - Abbott Molecular Inc. has initiated a recall of its automated real-time fluorescent nucleic acid amplification analysis system due to design defects [1] - Other companies including Ortho Clinical Diagnostics, Leica Biosystems, Beckman Coulter, and Aesculap have also recalled products due to various issues such as potential bias in reportable range, incorrect labeling, cross-contamination, and rising complaint trends [1] Drug and Device Approvals - Jianyou Co., Ltd. has received FDA approval for the production site transfer of its Idarubicin Hydrochloride Injection in multiple dosages [2] - Xinhua Pharmaceutical has been granted approval for the listing of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [3] Capital Market Activities - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, will be listed on the New Third Board starting May 20, 2025 [4] - Chuangxin International has completed nearly 100 million RMB in Series B financing led by Yueke Fund and Zhongshan Haochuang Fund [5] Industry Events - Kanghui Pharmaceutical has won a first-instance judgment in a lawsuit against Kelewei Biopharmaceuticals regarding equity repurchase, requiring Kelewei to pay 2 million RMB in deposit and 35.994 million RMB in repurchase funds [6] - Weigao Blood Purification Products Co., Ltd. has officially listed on the Shanghai Stock Exchange, raising approximately 1.09 billion RMB through its IPO [7] Public Sentiment Alerts - Sanleaf Bio has changed its accounting firm due to disagreements over audit fees [8] Management Changes - Dize Pharmaceutical's executives plan to reduce their shareholdings due to personal financial needs, with specific amounts detailed for each individual [9][10] - Jia Ying Pharmaceutical's CFO has resigned for personal reasons and will no longer hold any position within the company [11]

Core Insights - Shandong Weigao Blood Purification Products Co., Ltd. officially listed on the Shanghai Stock Exchange on May 19, marking a new chapter in its capital market journey [1] - The company has been dedicated to meeting the blood purification needs of global kidney disease patients for over 20 years, focusing on hemodialysis and peritoneal dialysis [1] Market Position - As of 2023, Weigao Blood Purification holds the leading market shares in China for hemodialysis devices and blood dialysis tubing, with shares of 32.5% and 31.8% respectively [2] - The company ranks second in the market for hemodialysis machines with a 24.6% market share, closely following Fresenius Medical [2] Financial Performance - Weigao Blood Purification reported revenues of 3.426 billion yuan, 3.532 billion yuan, and 3.604 billion yuan for the years 2022, 2023, and 2024 respectively [2] - The net profits attributable to shareholders were 315 million yuan, 442 million yuan, and 449 million yuan for the same years, indicating strong profitability and market resilience [2] Technological Advancements - The company is actively engaged in the research and development of core technologies related to biomedical membranes, significantly improving solute clearance rates by over 15% and reducing allergy risks for patients [3] - Weigao's technological breakthroughs have prompted international competitors to reassess their development directions, accelerating global advancements in blood purification technology [3] Investment and Growth Strategy - The IPO proceeds will primarily fund projects in intelligent production, the establishment of a hemodialysis device production base, R&D center development, and digital information technology platform construction [4] - Future R&D investments will focus on next-generation hemodialysis devices, innovative production equipment, and fully automated manufacturing equipment [5] Market Expansion - The company plans to enhance cooperation with grassroots medical institutions to increase product coverage in lower-tier cities and rural areas, capitalizing on the growing demand for blood purification equipment [5] - Weigao has been expanding its international presence since 2016, with a notable market share in Southeast Asia, particularly in Indonesia [5] Industry Outlook - The blood purification industry in China is poised for significant growth due to an aging population, rising chronic kidney disease prevalence, and improved treatment penetration rates [5] - The company aims to leverage capital market opportunities to enhance brand influence and contribute to the health of chronic kidney disease patients in China [5]

- The report tracks the recent performance of the offline IPO market for the STAR Market, ChiNext, and the Main Board, assuming all stocks are hit and sold at the market average price on the first day of listing, ignoring the lock-up period restrictions [1][11] - Since 2025 until 2025/5/16, the IPO yield for a Class A 2 billion account is 1.32%, and for a Class B 2 billion account is 1.15%; for a Class A 10 billion account, the IPO yield is 0.30%, and for a Class B 10 billion account, the IPO yield is 0.27% [1][11] - The median number of valid quotation accounts for recent 20 new stocks is tracked, with the number of valid quotation accounts for Class A STAR Market new stocks around 3051, and for Class B around 1784; for Class A ChiNext new stocks around 3414, and for Class B around 2056; for Class A Main Board stocks around 3493, and for Class B around 2376 [2][23] - The average first-day increase for STAR Market stocks is 198.41%, and for ChiNext stocks is 227.46% [1][16] - The report measures the theoretical IPO yield for different scale accounts, assuming all stocks are hit and sold at the market average price on the first day of listing, ignoring the lock-up period restrictions [1][11] - The report lists the IPO results for recent new stocks, including the issuance price, issuance P/E ratio, industry P/E ratio, number of new shares issued, and the actual fundraising amount [25][26] - The report provides a calendar of recent IPOs, including the status of stocks waiting for inquiry, waiting for issuance price announcement, waiting for subscription, and waiting for listing [27][28][29] - The report calculates the full subscription yield for each stock, using the average winning rate of Class A institutions to estimate the yield when fully subscribed [35][37] - The report lists the monthly IPO yield and IPO yield rate for different scale Class A accounts, assuming all stock quotations are included, with a 90% fund utilization efficiency [42][43][44][45][46] - The report lists the monthly IPO yield and IPO yield rate for different scale Class B accounts, assuming all stock quotations are included, with a 90% fund utilization efficiency [47][48][49][50][51]

Core Viewpoint - Weigao Blood Purification officially listed on the Shanghai Stock Exchange on May 19, 2023, raising approximately 1.09 billion yuan with a closing price of 41.41 yuan per share, a 56.26% increase from the issue price [1][2]. Group 1: Financial Performance - Weigao Blood Purification's revenue for 2024 is projected to be 3.604 billion yuan, a 2.04% increase from 2023 [3]. - The company reported a net profit of 449 million yuan for 2024, up 1.58% from 2023 [3]. - The average selling price of blood purification products has been declining, with the average factory price of blood purification devices dropping by 16% and 11% in 2024 [7][8]. Group 2: Market Position and Competition - The blood purification industry in China is facing intense competition, with international giants like Fresenius and Baxter dominating the market [1][4]. - Weigao Blood Purification holds the largest market share in the domestic blood purification device sector, with 32.5% for blood purification devices and 31.8% for blood purification tubing [5][6]. - The company’s blood purification machine revenue has been declining due to procurement delays, with revenues dropping from 660 million yuan in 2022 to 619 million yuan in 2024 [5][6]. Group 3: Business Strategy and Challenges - The funds raised from the IPO will be used for the construction of intelligent production facilities and the development of new high-performance consumables [1]. - The company faces challenges from reliance on joint ventures for key products, which could impact overall performance if partnerships deteriorate [7]. - The implementation of volume-based procurement policies is pressuring prices and profit margins, with projected declines in gross profit margins [8][12]. Group 4: R&D and Sales Dynamics - R&D expenses for Weigao Blood Purification are relatively low compared to sales expenses, with R&D accounting for only 4.57% of revenue in 2024 [9][10]. - The company has faced scrutiny regarding high sales expenses, which are approximately 20% of revenue, higher than comparable companies [10]. - The need for a balance between high R&D investment and compliance with regulations is a significant challenge for the company and the industry as a whole [12].

证券时报·数据宝统计，5月19日龙虎榜中营业部资金净卖出6.03亿元，其中，净买入的个股17只，净卖 出的个股23只。净买入较多个股分别是吉林化纤、C威高、拉芳家化等，净买入金额占当日成交额比例 达5.15%、7.15%、15.22%。此外，营业部净卖出居前个股分别为红宝丽、中欣氟材、宁波远洋等，净 卖出金额占当日成交额比例达14.01%、6.64%、5.18%。（数据宝） （数据释义：根据沪深交易所每日盘后公布的龙虎榜数据，买入金额减去卖出金额得到当日营业部净买 入额。）本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 5月19日龙虎榜营业部净买卖个股排名 | 代码 | 简称 | 收盘价（元） | 涨跌幅(%) | 营业部净买卖（万元） | 占当日成交额比(%) | | --- | --- | --- | --- | --- | --- | | 000420 | 吉林化纤 | 5.04 | 10.04 | 13180.17 | 5.15 | | 603014 | C威高 | 41.41 | 56.26 | 8218.42 | 7.15 | | 603630 | 拉芳家化 | ...

Market Overview - On May 19, the A-share major indices experienced slight fluctuations, with a total trading volume of 1.12 trillion yuan, a decrease of 5.2 billion yuan compared to the previous trading day, and over 3,500 stocks rose [1] - High-position stocks continued to attract capital, with the port and shipping sector experiencing a surge, while the robotics sector faced adjustments, and CRO-related stocks saw significant declines [1] High-Position Stocks - A total of 84 stocks hit the daily limit, with 23 stocks achieving consecutive limit-ups, and a limit-up rate of 79% (excluding ST and delisted stocks) [3] - Notable stocks included: - Chengfei Integration (9 consecutive limit-ups) - Lijun Shares (8 limit-ups in 9 days) - Yingfeng Shares (6 limit-ups in 7 days) - Nanjing Port, Lianyungang, and Ningbo Maritime (5 consecutive limit-ups) [3][4] Trading Data - Key trading data for selected stocks: - Chengfei Integration: Price 39.48 yuan, +10.00%, trading volume 25.19 million [4] - Lijun Shares: Price 15.59 yuan, +10.02%, trading volume 23.93 million [4] - Yingfeng Shares: Price 9.77 yuan, +10.02%, trading volume 5.50 million [4] - Nanjing Port: Price 11.25 yuan, +9.97%, trading volume 8.89 million [4] - Lianyungang: Price 8.20 yuan, +10.07%, trading volume 15.76 million [4] Institutional Trading - Top net purchases on the daily leaderboard included: - Jilin Chemical Fiber: 136 million yuan - Youfu Shares: 87.9 million yuan - Variety Shares: 72.02 million yuan [5] - Top net sales included: - Hongbaoli: -492 million yuan - Zhongxin Fluorine Materials: -131 million yuan - Lijun Shares: -101 million yuan [6] Company Highlights - Jilin Chemical Fiber announced a price increase for its wet 3k carbon fiber products, effective May 13, with a price hike of 10,000 yuan per ton due to high demand [8][9] - Youfu Shares confirmed no need for corrections or additional disclosures regarding its previous announcements, focusing on the production and sales of polyester industrial yarns and related materials [11] - Variety Shares is planning a major asset restructuring to gain control of Jiangsu Jilai Microelectronics, following regulatory encouragement for private equity participation in mergers and acquisitions [14] Stock Performance - Jilin Chemical Fiber: +10.04%, trading volume 25.61 billion yuan, with institutional net selling of 46.6 million yuan [21] - Youfu Shares: +10.04%, trading volume 15.33 billion yuan, with institutional net buying of 52.09 million yuan [20] - Lijun Shares: +10.02%, trading volume 23.92 billion yuan, with institutional net selling of 101 million yuan [18]

机构专用、机构专用、机构专用分别卖出2290.78万元、2092.00万元、1747.48万元。 买入金额最大的前5名营业部 买入额/万 卖出额/万 净额/万 东方财富证券股份有限公司拉萨东环路第一 证券营业部 2112.40 0.00 2112.4 国金证券股份有限公司上海浦东新区云鹃北路证券营业部 1664.90 0.00 1664.9 招商证券股份有限公司上海牡丹江路证券营业部 1531.80 0.00 1531.8 东方财富证券股份有限公司 拉萨东环路第二证券营业部 1457.75 0.00 1457.75 东方财富证券股份有限公司拉萨团结路第二证券营业 部 1451.57 0.00 1451.57 卖出金额最大的前5名营业部 买入额/万 卖出额/万 净额/万 机构专用 0.00 2290.78 -2290.78 机构专用 0.00 2092.00 -2092.0 机构专用 0.00 1747.48 -1747.48 机构专用 0.00 1631.32 -1631.32 机构专用 0.00 1503.18 -1503.18 5月19日，威高血净上涨56.26%登上龙虎榜，无价格涨跌幅限制。 龙虎榜显示 ...